Arrow Financial's 15min chart shows KDJ Death Cross and Bearish Marubozu.
ByAinvest
Wednesday, Sep 17, 2025 11:47 am ET1min read
AROW--
At Cryo-Cell International, Chairman and Co-CEO David Portnoy made a significant purchase of 42,900 shares on Wednesday, September 12, 2025. The shares were bought at a cost of $4.43 each, totaling an investment of $189,986. This latest buy follows several previous purchases by Portnoy, totaling $285,581 at an average price of $4.44 per share over the past year. As of Friday, September 14, 2025, Cryo-Cell International's stock has traded down by approximately 3.5% on the day, indicating a slight decline in share value [1].
Arrow Financial also saw insider buying activity on Wednesday, September 12, 2025. The company's Chief Financial Officer, Penko Krassimir Ivanov, purchased 5,000 shares at a cost of $29.10 each, totaling $145,499. This latest purchase builds upon Ivanov's previous investments in AROW, amounting to $391,248 over the past twelve months at an average price of $29.14 per share. As of Friday, September 14, 2025, Arrow Financial's stock has traded off by approximately 0.5% on the day, showing a minimal decrease in share value [1].
While these insider buys suggest a positive outlook from the executives, it is essential to consider the broader market conditions. For instance, Arrow Financial's 15-minute chart triggered a KDJ Death Cross and a Bearish Marubozu on September 17, 2025, at 11:45, indicating a shift in momentum towards the downside and a potential for further price decrease. Sellers are currently in control of the market, suggesting that bearish momentum may continue .
CCEL--
Arrow Financial's 15-minute chart has triggered a KDJ Death Cross and a Bearish Marubozu at 09/17/2025 11:45, indicating a shift in momentum towards the downside and a potential for further price decrease. Sellers are currently in control of the market, and it is likely that bearish momentum will continue.
In the realm of financial markets, insider buying can often signal a positive outlook on a company's future prospects. Two notable insider purchases were reported recently, shedding light on the sentiments of key executives at Cryo-Cell International (CCEL) and Arrow Financial (AROW).At Cryo-Cell International, Chairman and Co-CEO David Portnoy made a significant purchase of 42,900 shares on Wednesday, September 12, 2025. The shares were bought at a cost of $4.43 each, totaling an investment of $189,986. This latest buy follows several previous purchases by Portnoy, totaling $285,581 at an average price of $4.44 per share over the past year. As of Friday, September 14, 2025, Cryo-Cell International's stock has traded down by approximately 3.5% on the day, indicating a slight decline in share value [1].
Arrow Financial also saw insider buying activity on Wednesday, September 12, 2025. The company's Chief Financial Officer, Penko Krassimir Ivanov, purchased 5,000 shares at a cost of $29.10 each, totaling $145,499. This latest purchase builds upon Ivanov's previous investments in AROW, amounting to $391,248 over the past twelve months at an average price of $29.14 per share. As of Friday, September 14, 2025, Arrow Financial's stock has traded off by approximately 0.5% on the day, showing a minimal decrease in share value [1].
While these insider buys suggest a positive outlook from the executives, it is essential to consider the broader market conditions. For instance, Arrow Financial's 15-minute chart triggered a KDJ Death Cross and a Bearish Marubozu on September 17, 2025, at 11:45, indicating a shift in momentum towards the downside and a potential for further price decrease. Sellers are currently in control of the market, suggesting that bearish momentum may continue .
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet